Collectively, these findings advance the pharmacological landscape of GLP-1 and its derived peptides, suggesting that they are versatile agents for comprehensive treatment strategies for chronic pain syndromes linked with metabolic disorders. This evidence concerns the gene GCG and metabolic disease.